(NASDAQ: RIGL) Rigel Pharmaceuticals's forecast annual revenue growth rate of 9.62% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.8%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.47%.
Rigel Pharmaceuticals's revenue in 2026 is $294,282,000.On average, 7 Wall Street analysts forecast RIGL's revenue for 2026 to be $5,334,670,481, with the lowest RIGL revenue forecast at $5,078,078,706, and the highest RIGL revenue forecast at $5,549,512,983. On average, 7 Wall Street analysts forecast RIGL's revenue for 2027 to be $5,987,141,433, with the lowest RIGL revenue forecast at $5,355,175,656, and the highest RIGL revenue forecast at $6,932,411,495.
In 2028, RIGL is forecast to generate $7,283,031,503 in revenue, with the lowest revenue forecast at $5,846,191,451 and the highest revenue forecast at $10,895,267,343.